Biotech and Pharmaceuticals Medicine

More

  • Obama: Plans in place to develop Zika diagnostics

    President Obama speaks about the U.S. response to the Zika virus after a briefing from the CDC.

  • Obama: US Zika cases appear to be travel-related

    CNBC's Eamon Javers reports on President Obama's comments after a briefing on the Zika virus.

  • May 20- Some 157 pregnant women in the United States and another 122 in U.S. territories, primarily Puerto Rico, have tested positive for infection with the Zika virus, the U.S. Centers for Disease Control and Prevention said on Friday. The CDC, in a conference call, said that so far fewer than a dozen of the infected pregnant women it has tracked in the United States and...

  • CDC: 279 pregnant women infected with Zika

    CNBC's Meg Tirrell reports the latest Zika monitoring figures from the Centers for Disease Control for the United States.

  • CDC SAYS FEWER THAN ONE DOZEN ZIKA-INFECTED PREGNANT WOMEN IN U.S., PUERTO RICO, HAVE HAD ADVERSE OUTCOMES, SUCH AS MISCARRIAGES, BIRTH DEFECTS.

  • May 20- Some 157 pregnant women in the United States and another 122 in U.S. territories have tested positive for infection with the Zika virus, the U.S. Centers for Disease Control and Prevention said on Friday. It was the first time the agency had disclosed the number of Zika-infected pregnant women in the U.S. and its territories. U.S. health officials have...

  • WELKOM, South Africa— Thabang Moorosi, a former driller in South Africa's gold mines, takes a minute to catch his breath after struggling onto a hospital bed for his monthly lung check. He is one of tens of thousands of miners preparing to sue some of South Africa's largest gold mining companies, including Anglo American, AngloGold Ashanti, Harmony Gold and...

  • Targeting cancer

    Robert Mulroy, Merrimack Pharmaceuticals CEO, discusses the company's oncology pipeline and clinical basket trial.

  • May 19- Tonix Pharmaceuticals Holding Corp said a higher dose of its experimental drug reduced symptoms in post-traumatic stress disorder patients, offering hope of a new treatment for the mental condition in more than 15 years. The company's shares rose as much as 30 percent to $3.77 in early trading on Thursday but pared gains to be up 6 percent in morning...

  •  Woman silhouette with cityscape

    A disease that affects 1 in 10 US women has a cost of $119 billion in lost productivity, and not enough is being done to combat it.

  • May 19- Tonix Pharmaceuticals Holding Corp said a higher dose of its experimental drug for post-traumatic stress disorder helped control symptoms in patients, sending its shares surging 46 percent in premarket trading. Tonix said it would take the 5.6 mg dose into late-stage trials after discussions with the U.S. Food and Drug Administration.

  • NEW YORK, May 19- Health insurer Cigna Corp plans to cut its customers' prescriptions for opioid treatments by 25 percent over the next three years, putting its weight behind a U.S. government battle against addictive painkillers. President Barack Obama earlier this year asked Congress for $1.1 billion in new funding over two years to expand treatment for a...

  • May 19- Drug developer Tonix Pharmaceuticals Holding Corp said on Thursday a higher dose of its experimental drug for post-traumatic stress disorder was successful in reducing severity of symptoms related to the psychiatric disorder. Tonix's shares rose 38 percent in premarket trading. A 5.6 mg dose of the drug showed promise, but the lower 2.8 mg dose did not...

  • CHICAGO— A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. The drug, which targets the immune system, was used to treat former President Jimmy Carter, who was diagnosed with melanoma that had spread to his brain. Caroline Robert, the study's lead author, said of the results released Wednesday.

  • May 18- An experimental Pfizer drug that helps the immune system fight cancer showed early promise against a variety of cancers when used with Merck& Co's immunotherapy Keytruda in a small clinical trial, according to data released on Wednesday. The first wave of successful cancer immunotherapies, such as Keytruda, block mechanisms that tumors use to evade the...

  • Some 28,000 women in the United States have received Ibrance therapy since the accelerated approval, Pfizer said. That compared with 14.5 months for women who received letrozole and a placebo, according to a brief summary of data that will be presented next month at the American Society of Clinical Oncology meeting in Chicago. The 10- month difference, deemed...

  • PFIZER'S IBRANCE SUCCEEDS IN LARGE CONFIRMATORY TRIAL IN ADVANCED BREAST CANCER.

  • NEW YORK, May 18- Two new drugs that help the immune system fight some of the deadliest cancers are helping patients live years longer than older treatments, according to clinical trial results that should further boost confidence in this approach to oncology. The results were released on Wednesday ahead of the American Society of Clinical Oncology meeting in...

  • Tecentriq won accelerated approval Wednesday from the Food and Drug Administration for treating patients with advanced urothelial cancer after chemotherapy stops helping them— a point when most usually die within about six months. Testing on many more patients to confirm the early results, which is required to obtain full approval from the FDA, is in...

  • May 18- The U.S. Food and Drug Administration on Wednesday granted accelerated approval for Roche Holding AG's immunotherapy for the most common form of bladder cancer, marking the company's entry into a lucrative class of drugs. The drug, Tecentriq, targets the PD-1/PD-L1 pathway, which helps the immune system fight cancer by blocking a mechanism tumors use to...